Asterotide
Generic Name
Octreotide
Packs Price
- Inj 0.1 mg: 1 Ampx1 ml: 408.74: 480.88
Company
Aster Life Science
Therapeutic Group
Pituitary And Hypothalamic Hormones And Analogues
Indication Dosage
Symptoms Associated With Carcinoid Tumours With Features Of Carcinoid Syndrome, Vipomas, and Glucagonomas:
By Sc Inj:
- Adult: Initially 50 Mcg 1-2 Times A Day, Adjusted According To Response; Increased To 200 Mcg 3 Times A Day, Higher Doses May Be Required Exceptionally; Maintenance Doses Are Variable; In Carcinoid Tumours, Discontinue After 1 Week If No Effect, If Rapid Response Required, Initial Dose May Be Given By IV Injection (with Ecg Monitoring And After Dilution)
Acromegaly, Short-term Treatment Before Pituitary Surgery Or Long-term Treatment In Those Inadequately Controlled By Other Treatment Or Until Radiotherapy Becomes Fully Effective:
By Sc Inj:
- Adult: 100-200 Mcg 3 Times A Day, Discontinue If No Improvement Within 3 Months
Prevention Of Complications Following Pancreatic Surgery:
By Sc Inj:
- Adult: (consult Product Literature)
Test Dose Before Use Of Depot Preparation:
By Sc Inj:
- Adult: Test Dose 50-100 Mcg For 1 Dose, Test Dose Should Be Given If Subcutaneous Octreotide Not Previously Given
Acromegaly, Neuroendocrine (particularly Carcinoid) Tumour Adequately Controlled By Subcutaneous Octreotide:
By Deep IM Inj Using Depot Inj:
- Adult: Initially 20 Mg Lar Injection Every 4 Weeks For 3 Months Then Adjusted According To Response, Increased If Necessary Up To 30 Mg Lar Injection Every 4 Weeks, To Be Administered Into The Gluteal Muscle, For Acromegaly, Start Depot 1 Day After The Last Dose Of Subcutaneous Octreotide, For Neuroendocrine Tumours, Continue Subcutaneous Octreotide For 2 Weeks After First Dose Of Depot Octreotide
Advanced Neuroendocrine Tumours Of The Mid Gut, Or Tumours Of Unknown Primary Origin Where Non-mid Gut Sites Of Origin Have Been Excluded:
By Deep IM Inj Using Depot Inj:
- Adult: 30 Mg Lar Injection Every 4 Weeks
Reduce Intestinal Secretions In Palliative Care and reduce Vomiting Due To Bowel Obstruction In Palliative Care: By Continuous Sc Infusion:
- Adult: 0.25-0.5 Mg/24 Hours (max. Per Dose0.75 Mg/24 Hours), Occasionally Doses Higher Than The Maximum Are Sometimes Required
Content
- Inj 0.05mg /0.1mg: Per 1 ml Amp: Octreotide (as Acetate) 0.05mg /0.1mg; Solution.
- Inj: Octreotide (as Acetate) 20mg; Micro-spheres For Susp; In Vials Plus 2 Amp Of Diluent, Syringe And 2 N
Pregnancy
Consult with Doctor Or Caution Advised
Stability
Contra Indications
Precautions
Lactation
- Consult with Doctor Or Caution Advised
Side Effects
- Alopecia
- Arrhythmias
- Biliary Colic (associated With Abrupt Withdrawal Of Subcutaneous Octreotide)
- Bradycardia
- Dehydration
- Dizziness
- Dyspnea
- Headache
- Hepatitis
- Pancreatitis (associated With Abrupt Withdrawal Of Subcutaneous Octreotide)
- Rash